Combine radiotherapy and immunotherapy in esophageal squamous cell carcinoma
- PMID: 37633347
- DOI: 10.1016/j.critrevonc.2023.104115
Combine radiotherapy and immunotherapy in esophageal squamous cell carcinoma
Abstract
Immune checkpoint inhibitors(ICIs) have improved the survival of advanced esophageal squamous cell carcinoma (ESCC) patients. Radiotherapy is one of the common therapies to treat esophageal cancer. However, whether combination radiation therapy can increase the efficacy of immunotherapy is still up for debate. Radiotherapy combined with immunotherapy has proven to be a reliable and effective treatment for tumors, and it can work in combination with immunotherapy to achieve better anti-tumor effects. This review aims to discuss the efficacy and safety of combining radiotherapy and immunotherapy to treat ESCC by stages as well as the optimum radiotherapy dose and target volume, with a summary of clinical trials in ESCC.
Keywords: Esophageal squamous cell carcinoma; Immunotherapy; Locally advanced; Neoadjuvant; Radiotherapy.
Copyright © 2023 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
